Recent Finacing
Recent Raise
Antikor Biopharma develops single-chain Fv-based fragment–drug conjugates (FDCs) and linker–payload technologies for higher payload loading, aiming to improve tumor penetration and reduce normal tissue exposure; lead ANT043 targets HER2.
